Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in MEN Patients
PRRT (peptide receptor radionuclide therapy using radiolabeled somatostatin analogs) showed safety and efficacy in treating neuroendocrine tumors in patients with multiple endocrine neoplasia syndromes.
Quick Facts
What This Study Found
PRRT with radiolabeled somatostatin analogs was safe and effective for neuroendocrine tumors in MEN patients, extending this peptide-targeted therapy to a complex and underserved population.
Key Numbers
Up to 4 cycles of ¹⁷⁷Lu-DOTATATE (5.5-7.4 GBq per cycle) administered every 8-12 weeks.
How They Did This
Clinical study of PRRT safety and efficacy in MEN patients with neuroendocrine tumors. Assessed tumor response, survival outcomes, and adverse events.
Why This Research Matters
MEN patients have complex multi-tumor disease and limited treatment options. Demonstrating PRRT safety and efficacy in this population expands access to peptide-targeted radiation therapy for patients who need it most.
The Bigger Picture
PRRT represents one of the most successful clinical applications of therapeutic peptides — using somatostatin analog peptides as targeted delivery vehicles for radiation. Expanding this to MEN patients demonstrates the versatility of peptide-targeted therapy in complex oncological settings.
What This Study Doesn't Tell Us
MEN patients represent a small, heterogeneous population. Study size may be limited. Long-term outcomes in MEN patients need follow-up.
Questions This Raises
- ?Should PRRT be considered earlier in MEN patient treatment algorithms?
- ?How do MEN patient PRRT outcomes compare to sporadic neuroendocrine tumor patients?
- ?Can PRRT be combined with other targeted therapies for MEN tumors?
Trust & Context
- Key Stat:
- Peptide-targeted radiation Somatostatin analog peptides deliver radiation directly to neuroendocrine tumors in MEN patients, with demonstrated safety and efficacy
- Evidence Grade:
- Moderate evidence: clinical study in a specific patient population extending known PRRT benefits to MEN patients.
- Study Age:
- Published in 2025. Extends PRRT evidence to multiple endocrine neoplasia syndromes.
- Original Title:
- Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience.
- Published In:
- Clinical nuclear medicine, 50(7), 605-611 (2025)
- Authors:
- Aggarwal, Piyush(2), Satapathy, Swayamjeet(2), Kaur, Gurjeet, Sood, Ashwani, Bhadada, Sanjay Kumar, Walia, Rama, Gupta, Rajesh, Mittal, Bhagwant Rai
- Database ID:
- RPEP-09784
Evidence Hierarchy
Frequently Asked Questions
What is PRRT?
Peptide receptor radionuclide therapy attaches a radioactive atom to a somatostatin analog peptide. When injected, the peptide seeks out and binds to somatostatin receptors on neuroendocrine tumors, delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue.
Can MEN patients receive PRRT?
This study shows yes — PRRT was safe and effective in MEN patients with neuroendocrine tumors. While MEN patients were often excluded from earlier PRRT trials due to their complex multi-tumor disease, this study supports its use in this population.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09784APA
Aggarwal, Piyush; Satapathy, Swayamjeet; Kaur, Gurjeet; Sood, Ashwani; Bhadada, Sanjay Kumar; Walia, Rama; Gupta, Rajesh; Mittal, Bhagwant Rai. (2025). Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience.. Clinical nuclear medicine, 50(7), 605-611. https://doi.org/10.1097/RLU.0000000000005891
MLA
Aggarwal, Piyush, et al. "Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience.." Clinical nuclear medicine, 2025. https://doi.org/10.1097/RLU.0000000000005891
RethinkPeptides
RethinkPeptides Research Database. "Safety and Efficacy of Peptide Receptor Radionuclide Therapy..." RPEP-09784. Retrieved from https://rethinkpeptides.com/research/aggarwal-2025-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.